Opus Genetics Inc
IRD
NASDAQ
Biotechnology
$3.61
USD
-0.11 (-2.96%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $309.49M
Volume 414.2K
Revenue
$9.86M
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-107.61M
TTM
— YoY
Operating Cash Flow
$-40.67M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2.9 | 3.1 | 3.9 | 2.2 | 0.8 |
YoY Growth | — | — | -10.2% | -50.6% | -73.8% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 2.9 | 3.1 | 3.9 | 2.2 | 0.8 |
Selling, General & Administrative | 5.8 | 5.0 | 4.9 | 5.9 | 6.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.8 | 11.4 | 15.3 | 16.5 | 17.2 |
Operating Income | -8.9 | -8.3 | -11.5 | -14.4 | -16.5 |
EBITDA | -8.9 | -8.3 | -11.4 | -14.4 | -16.5 |
Other Income / Expense | 1.5 | -9.1 | -6.3 | -50.5 | 8.9 |
Total Other Income / Expense | 1.5 | -9.1 | -5.1 | -51.2 | 8.4 |
Income Before Income Taxes | -7.4 | -17.5 | -16.5 | -65.5 | -8.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -7.4 | -17.5 | -16.5 | -65.5 | -8.1 |
Consolidated Net Income / Loss | -7.4 | -17.5 | -16.5 | -65.5 | -8.1 |
Net Income Attributable to Common Shareholders | -7.4 | -17.5 | -16.5 | -65.5 | -8.1 |
Basic EPS | -$0.12 | -$0.25 | -$0.20 | -$0.75 | -$0.08 |
Diluted EPS | -$0.12 | -$0.25 | -$0.20 | -$0.75 | -$0.14 |
Basic Shares Outstanding | 63.4M | 70.6M | 81.0M | 86.9M | 95.5M |
Diluted Shares Outstanding | 63.4M | 70.6M | 81.0M | 86.9M | 111.4M |